Welcome to our dedicated page for Quantum-Si Incorporated SEC filings (Ticker: QSI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles U.S. SEC filings for Quantum-Si Incorporated (Nasdaq: QSI), a proteomics technology and life sciences company focused on single-molecule protein analysis and Next-Generation Protein Sequencing. Here, investors can review how Quantum-Si reports its financial performance, capital structure, and material corporate events in official regulatory documents.
Quantum-Si’s periodic reports, such as its quarterly results furnished via Form 8-K, provide detail on product and service revenue, cost of revenue, research and development spending, selling, general and administrative expenses, and items like lease termination or legal settlement expenses. These filings also include condensed consolidated balance sheets and statements of operations, along with non-GAAP metrics such as adjusted total operating expenses and adjusted EBITDA, together with reconciliations to GAAP measures.
Capital markets and financing activities are documented in Forms 8-K and related registration statements. Examples include a registered direct offering of Class A common stock and pre-funded warrants, an at-the-market Sales Agreement for Class A common stock, and the termination of a prior equity distribution agreement. Filings describe intended uses of proceeds, such as funding the Proteus platform development, commercialization, manufacturing development, research and development, and general corporate purposes.
Other material agreements and corporate actions, including lease terminations, settlement and mutual release agreements, and inducement equity awards under the 2023 Inducement Equity Incentive Plan, are also reported in Quantum-Si’s SEC filings. Stock Titan’s interface adds AI-powered summaries that highlight key terms, financial impacts, and timelines from these documents, helping readers quickly understand complex agreements, capital raises, and operating decisions without reading every line of each filing.
Quantum-Si Inc (QSI) insider sale summary: John S. Vieceli, identified as Chief Product Officer and a director-level reporting person, disclosed sales of Class A common stock tied to the vesting of previously granted restricted stock units. On 09/22/2025 he sold 9,843 shares at a weighted average price of $1.6826 per share and reported beneficial ownership of 832,743 shares after that sale. On 09/23/2025 he sold another 9,843 shares at a weighted average price of $1.635 per share and reported beneficial ownership of 822,900 shares thereafter. The filing states these sales were mandatory "sell-to-cover" transactions to satisfy federal, state and local withholding taxes and that the reporting individual could not alter that provision.
Jeffry R. Keyes, Chief Financial Officer of Quantum-Si Inc. (QSI), reported two routine stock sales tied to vested restricted stock units. The filing shows sales on 09/22/2025 and 09/23/2025 of 3,873 shares each day under a mandatory sell-to-cover provision used to satisfy federal, state and local tax withholding on vesting RSUs. The weighted average sale prices were $1.6826 (shares sold ranged $1.64–$1.72) and $1.635 (shares sold ranged $1.57–$1.79). Beneficial ownership reported after the transactions was 1,175,697 shares following the 09/22 sale and 1,171,824 shares following the 09/23 sale. The filer notes the sell-to-cover is mandatory and not subject to trustee election; the form was signed by an attorney-in-fact on 09/24/2025.
Bennett Todd C., Chief Commercial Officer and director of Quantum-Si Inc. (QSI), reported two mandatory sell-to-cover transactions tied to vested restricted stock units on 09/22/2025 and 09/23/2025. On each date he sold 18,482 shares of Class A common stock, totaling 36,964 shares sold to cover required federal, state and local withholding taxes.
The weighted average sale prices reported were $1.6826 on 09/22/2025 (shares sold ranged $1.64–$1.72) and $1.635 on 09/23/2025 (shares sold ranged $1.57–$1.79). Following the transactions, beneficial ownership was reported as 700,003 shares and then 681,521 shares, respectively. The filing was signed by an attorney-in-fact on 09/24/2025.
Jonathan M. Rothberg and affiliated entities disclosed holdings in Quantum-Si Inc. across both Class A and Class B stock classes and filed Amendment No. 4 to their Schedule 13D. For Class A, the filing reports beneficial ownership of 14,276,415 shares, representing 7.8% of the 182,557,698 Class A shares outstanding as of July 31, 2025; that amount includes personal shares, options exercisable within 60 days, and shares held by trusts and affiliated entities.
The filing also reports beneficial ownership of 19,937,500 Class B shares, representing 100% of outstanding Class B stock. As part of estate planning, trusts for Dr. Rothberg's children adopted a Rule 10b5-1 trading plan allowing sales of up to 8,973,841 Class A shares during the plan period from January 14, 2026 through January 14, 2027, subject to minimum price parameters; no assurance any sales will occur. The amendment adds the Rule 10b5-1 plan as Exhibit 5.
Quantum-Si Incorporated posted an updated corporate presentation to its investor website on August 8, 2025. The company says it distributes slides and presentations from time to time to provide updates and summaries of its business, and the updated presentation slides are available in the "Investors" section at https://ir.quantum-si.com. The presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The filing explicitly states the information, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, nor incorporated by reference into registration statements except by specific reference. The report also lists Exhibit 104 (cover page interactive data file) and is signed by Chief Financial Officer Jeffry Keyes.
Quantum-Si Incorporated — Condensed Q2 2025 summary
For the six months ended June 30, 2025, total revenue was $1.433 million versus $1.079 million in H1 2024, with gross profit of $0.837 million. Net loss for the six months was $48.0 million (basic and diluted loss per share $0.26); loss for the three months ended June 30, 2025 was $28.8 million (loss per share $0.16). Operating expense drivers: R&D $28.93 million and SG&A $23.78 million for H1 2025.
Balance sheet and liquidity: cash and cash equivalents $22.188 million, marketable securities $192.023 million (total liquid assets ~$214.2 million). Net cash used in operating activities for H1 2025 was $46.351 million. The Company completed a January 3, 2025 registered direct offering (gross $50.0 million; net proceeds ~$46.8 million) and management expects current liquidity to fund operations for at least 12 months from issuance date. Material items: accrued legal settlement liability $8.0 million and related insurance receivable $4.638 million recorded as of June 30, 2025; warrant liabilities fair value declined to $2.6 million from $5.0 million at year-end 2024. Accumulated deficit as of June 30, 2025 was $644.7 million.